The Khorana Risk Score model. The Khorana Risk Score was originally derived from a development cohort of 2701 ambulatory cancer patients initiating chemotherapy and was then validated in an independent cohort of 1365 patients from a prospective registry. Rates of VTE in the derivation and validation cohorts are shown at the top.²⁷